John Pinion

John is a non-executive director of Aroa Biosurgery.

He is a resident of the United States and has been a director of Aroa Biosurgery since February 2015.

He has over 26 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. His expertise and leadership spans engineering, quality, manufacturing and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx’s translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. As a key member of Ultragenyx’s executive leadership team reporting directly to the organization’s CEO, he also contributes to ongoing business development, clinical development, commercial and strategic planning activities. John is also an Advisory Board Member for Celestial Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation novel and groundbreaking mRNA vaccines and therapeutics for the treatment and prevention of a variety of infectious diseases, rare diseases and cancers. John has previously held operational and senior leadership roles in Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland.

Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International’s Renal, Bioscience, Parenterals and Device divisions. He holds a B.S. in Mechanical Engineering from West Virginia University. John is considered by the Board to be an independent Director and is a member of the Audit and Risk Committee.